Synexus expands clinical trial operations in Gydnia, Poland

Synexus, the world's largest multi-national company dedicated to the recruitment and running of clinical trials is expanding its operations in Gydnia, Poland when it moves to new premises later this year. It has also recently increased the capacity of its original centre in Wroclaw by several hundred square metres.

The new dedicated research centre in Gydnia will have the capacity for four full-time investigators, with an increase from one hundred to three hundred square metres of space and will include a wide range of diagnostic instruments to cover Synexus' expanding therapy area coverage.

Dr Radoslaw Janiak, Synexus Country Manager for Poland says he is delighted with Synexus' progress in Poland: "Being part of Synexus' worldwide operations means that we are increasingly involved in large global clinical trials, we are able to recruit the right numbers of patients within the right time frame and that's exactly what sponsors are looking for. We are seeing considerable interest from a number of leading pharmas and CROs who are keen on the developments we have underway to increase our capacity here. In addition, the conference we organised in December has helped to raise awareness of the importance of clinical trials in Poland and has caught the attention of a number of senior medical professionals keen to develop their role and that of their organisation, in the vital area of clinical research and the importance of the sector to improving healthcare in Poland."

Synexus has been operating in Poland since 2006 from its site in Wroclaw and expanded its operations there in August 2009 when it acquired three new dedicated research centres in Warsaw, Gdynia and Katowice, following its takeover of CLCC.

Chief Executive Michael Fort believes that there is substantial scope to develop his company's business in Poland: "We are continuing to see increased levels of interest for clinical trials throughout the CEE, not least in Poland where our sites are very well located and staffed by highly qualified and experienced professionals. The pharma companies and CROs we are talking to continue to express their enthusiasm for increased capacity across the CEE and we are keen to help meet their demands."